---
schema_version: "secwatch.filing_event.v1"
accession: "0000059478-26-000008"
form_type: "8-K"
ticker: "LLY"
cik: "0000059478"
company_name: "ELI LILLY & Co"
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T05:07:53.265801+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lilly Q4 revenue up 43% to $19.3B; EPS $7.39 (+51%); FY2026 guidance $80-83B

## Summary
- Q4 revenue $19.3B (+43% YoY); reported EPS $7.39 (+51%); non-GAAP EPS $7.54 (+42%), both incl. $0.52 acquired IPR&D.
- FY2026 guidance: revenue $80-83B; non-GAAP EPS $33.50-$35.00.
- FDA approved Kwikpen for tirzepatide; filed orforglipron for obesity in US, Japan, and EU.
- Positive Phase 3 results for Taltz+Zepbound combo in psoriatic arthritis and retatrutide for knee osteoarthritis.
- Agreement with U.S. government to expand access to obesity medicines for millions of Americans.

## SEC filing metadata
- accession: 0000059478-26-000008
- form_type: 8-K
- ticker: LLY
- cik: 0000059478
- company_name: ELI LILLY & Co
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/59478/000005947826000008/0000059478-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/59478/000005947826000008/lly-20260204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000059478-26-000008
- JSON: https://secwatch.observer/filing/0000059478-26-000008.json
- Plain text: https://secwatch.observer/filing/0000059478-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.